Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption
Voyageur Announces Update To Non-Brokered Life Offering
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion
Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
Voyageur Pharmaceuticals partners with VAST on Frances Creek permitting work
Voyageur Advances Frances Creek Barite Project with VAST Engagement for Bulk Sample Permit
Voyageur Pharmaceuticals Grants Deferred Share Units and Options and Accelerates Expiry Date of Warrants
Voyageur Pharmaceuticals Signs LOI for Latin America Distribution Partnership Supporting Global Market Expansion
Voyageur Pharmaceuticals books first commercial sale with barium contrast agents order
Voyageur Pharmaceuticals appoints executive vice president to lead market expansion initiatives
Voyageur Pharmaceuticals Announces Appointment of Ethan Mohan as Executive Vice President
Voyageur Pharmaceuticals Announces Changes to Board of Directors and DSU Grant
Voyageur Pharmaceuticals launches contrast media product line following successful clinical results
Voyageur Pharmaceuticals Grants Deferred Share Units
Voyageur Pharmaceuticals nears Canadian market launch with completion of human testing
Voyageur Pharmaceuticals Advances Frances Creek Project, Paving the Way for a Secure, Vertically Integrated Barium Contrast Product Line
Voyageur Clarifies Terms of Previously Announced Agreement
Voyageur Pharmaceuticals Grants Deferred Share Units
Voyageur Pharmaceuticals secures grant to advance barium sulfate project - ICYMI
Voyageur Pharmaceuticals launches C$1M private placement
Voyageur Announces Proposed Private Placement
Voyageur Pharmaceuticals Grants Stock Options
Voyageur Pharmaceuticals adds new vice president of business development
Voyageur Pharmaceuticals welcomes new chief science officer
Voyageur Pharmaceuticals completes formulation of innovative diagnostic products, eyes FDA approval
Voyageur Pharmaceuticals CEO shares major progress in MRI drug innovation with Rain Cage
Voyageur Pharmaceuticals announces new collaboration with Rain Cage Carbon
Voyageur Pharmaceuticals announces collaboration with Rain Cage Carbon
Voyageur Pharmaceuticals partner Rain Cage Carbon and Toyota Tsusho Canada forge alliance for sustainable automotive solutions
Voyageur Pharmaceuticals wins US$1.9M sales contract for SmoothX 2% barium contrast product
Voyageur Pharmaceuticals poised to shake up medical imaging market with API partnership
Voyageur Pharmaceuticals to fast-track commercialization of imaging contrast agents through API partnership
Voyageur Pharmaceuticals initiates international expansion with 'pivotal' alliance
Voyageur Pharmaceuticals achieves milestone in the development of HDXBa barium contrast media
Voyageur Pharmaceuticals appoints seasoned executive to board; files interim financial statements
Large-scale fullerene production opens up world of possibilities in medicine, electronics
Voyageur Pharmaceuticals says white paper highlights SmoothX's potential as oral contrast agent
Voyageur Pharmaceuticals completes field work at Frances Creek project in British Columbia
Voyageur Pharmaceuticals unveils pioneering agreement with Rain Cage Carbon
Voyageur Pharmaceuticals aims to be the first vertically-integrated North American supplier of medical imaging contrast agents